198 related articles for article (PubMed ID: 34211033)
41. Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa Depression Study.
Melartin TK; Rytsälä HJ; Leskelä US; Lestelä-Mielonen PS; Sokero TP; Isometsä ET
J Clin Psychiatry; 2002 Feb; 63(2):126-34. PubMed ID: 11874213
[TBL] [Abstract][Full Text] [Related]
42. Risk of Substance Use Disorder and Its Associations With Comorbidities and Psychotropic Agents in Patients With Autism.
Huang JS; Yang FC; Chien WC; Yeh TC; Chung CH; Tsai CK; Tsai SJ; Yang SS; Tzeng NS; Chen MH; Liang CS
JAMA Pediatr; 2021 Feb; 175(2):e205371. PubMed ID: 33394019
[TBL] [Abstract][Full Text] [Related]
43. Major depressive disorder in vulnerable groups of older adults, their course and treatment, and psychiatric comorbidity.
Chou KL; Cheung KC
Depress Anxiety; 2013 Jun; 30(6):528-37. PubMed ID: 23423971
[TBL] [Abstract][Full Text] [Related]
44. Substance use and the treatment of resistant depression in adolescents.
Goldstein BI; Shamseddeen W; Spirito A; Emslie G; Clarke G; Wagner KD; Asarnow JR; Vitiello B; Ryan N; Birmaher B; Mayes T; Onorato M; Zelazny J; Brent DA
J Am Acad Child Adolesc Psychiatry; 2009 Dec; 48(12):1182-92. PubMed ID: 19858762
[TBL] [Abstract][Full Text] [Related]
45. Psychiatric comorbidity in treatment-seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study.
van Emmerik-van Oortmerssen K; van de Glind G; Koeter MW; Allsop S; Auriacombe M; Barta C; Bu ET; Burren Y; Carpentier PJ; Carruthers S; Casas M; Demetrovics Z; Dom G; Faraone SV; Fatseas M; Franck J; Johnson B; Kapitány-Fövény M; Kaye S; Konstenius M; Levin FR; Moggi F; Møller M; Ramos-Quiroga JA; Schillinger A; Skutle A; Verspreet S; ; van den Brink W; Schoevers RA
Addiction; 2014 Feb; 109(2):262-72. PubMed ID: 24118292
[TBL] [Abstract][Full Text] [Related]
46. Eating disorder recovery is associated with absence of major depressive disorder and substance use disorders at 22-year longitudinal follow-up.
Keshishian AC; Tabri N; Becker KR; Franko DL; Herzog DB; Thomas JJ; Eddy KT
Compr Psychiatry; 2019 Apr; 90():49-51. PubMed ID: 30685636
[TBL] [Abstract][Full Text] [Related]
47. Serum IL-7 and G-CSF in major depressive disorder.
Lehto SM; Huotari A; Niskanen L; Herzig KH; Tolmunen T; Viinamäki H; Koivumaa-Honkanen H; Honkalampi K; Sinikallio S; Ruotsalainen H; Hintikka J
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):846-51. PubMed ID: 20382196
[TBL] [Abstract][Full Text] [Related]
48. Independent versus substance-induced major depressive disorder in substance-dependent patients: observational study of course during follow-up.
Nunes EV; Liu X; Samet S; Matseoane K; Hasin D
J Clin Psychiatry; 2006 Oct; 67(10):1561-7. PubMed ID: 17107247
[TBL] [Abstract][Full Text] [Related]
49. Six-month treatment outcomes of cocaine-dependent patients with and without PTSD in a multisite national trial.
Najavits LM; Harned MS; Gallop RJ; Butler SF; Barber JP; Thase ME; Crits-Christoph P
J Stud Alcohol Drugs; 2007 May; 68(3):353-61. PubMed ID: 17446974
[TBL] [Abstract][Full Text] [Related]
50. Borderline personality and substance use in women.
Feske U; Tarter RE; Kirisci L; Pilkonis PA
Am J Addict; 2006; 15(2):131-7. PubMed ID: 16595350
[TBL] [Abstract][Full Text] [Related]
51. Sex Differences in Plasma Lysophosphatidic Acid Species in Patients with Alcohol and Cocaine Use Disorders.
Flores-López M; García-Marchena N; Araos P; Requena-Ocaña N; Porras-Perales O; Torres-Galván S; Suarez J; Pizarro N; de la Torre R; Rubio G; Ruiz-Ruiz JJ; Rodríguez de Fonseca F; Serrano A; Pavón-Morón FJ
Brain Sci; 2022 Apr; 12(5):. PubMed ID: 35624975
[TBL] [Abstract][Full Text] [Related]
52. Influence of comorbid alcohol use disorders on the clinical patterns of major depressive disorder: A general population-based study.
Carton L; Pignon B; Baguet A; Benradia I; Roelandt JL; Vaiva G; Thomas P; Amad A; De Timary P; Naassila M; Geoffroy PA; Rolland B
Drug Alcohol Depend; 2018 Jun; 187():40-47. PubMed ID: 29626745
[TBL] [Abstract][Full Text] [Related]
53. Attention-deficit/hyperactivity disorder and substance use: symptom pattern and drug choice.
Clure C; Brady KT; Saladin ME; Johnson D; Waid R; Rittenbury M
Am J Drug Alcohol Abuse; 1999 Aug; 25(3):441-8. PubMed ID: 10473007
[TBL] [Abstract][Full Text] [Related]
54. The effects of substance use disorder on the clinical presentation of anxiety and depression in an outpatient psychiatric clinic.
Tsuang D; Cowley D; Ries R; Dunner DL; Roy-Byrne PP
J Clin Psychiatry; 1995 Dec; 56(12):549-55. PubMed ID: 8530330
[TBL] [Abstract][Full Text] [Related]
55. Plasma Lysophosphatidic Acid Concentrations in Sex Differences and Psychiatric Comorbidity in Patients with Cocaine Use Disorder.
Requena-Ocaña N; Flores-López M; García-Marchena N; Pavón-Morón FJ; Pedraza C; Wallace A; Castilla-Ortega E; Rodríguez de Fonseca F; Serrano A; Araos P
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958570
[TBL] [Abstract][Full Text] [Related]
56. Gender-specific effects of comorbid depression and anxiety on the propensity to drink in negative emotional states.
Karpyak VM; Biernacka JM; Geske JR; Abulseoud OA; Brunner MD; Chauhan M; Hall-Flavin DK; Lewis KA; Loukianova LL; Melnyk GJ; Onsrud DA; Proctor BD; Schneekloth TD; Skime MK; Wittkopp JE; Frye MA; Mrazek DA
Addiction; 2016 Aug; 111(8):1366-75. PubMed ID: 27009547
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of plasma cytokines in patients with cocaine use disorders in abstinence identifies transforming growth factor alpha (TGFα) as a potential biomarker of consumption and dual diagnosis.
Maza-Quiroga R; García-Marchena N; Romero-Sanchiz P; Barrios V; Pedraz M; Serrano A; Nogueira-Arjona R; Ruiz JJ; Soria M; Campos R; Chowen JA; Argente J; Torrens M; López-Gallardo M; Marco EM; Rodríguez de Fonseca F; Pavón FJ; Araos P
PeerJ; 2017; 5():e3926. PubMed ID: 29038767
[TBL] [Abstract][Full Text] [Related]
58. Attention Deficit/Hyperactivity Disorder and Global Severity Profiles in Treatment-Seeking Patients with Substance Use Disorders.
Icick R; Moggi F; Slobodin O; Dom G; Mathys F; van den Brink W; Levin FR; Blankers M; Kaye S; Demetrovics Z; van de Glind G; Velez-Pastrana MC; Schellekens ASA;
Eur Addict Res; 2020; 26(4-5):201-210. PubMed ID: 32570249
[TBL] [Abstract][Full Text] [Related]
59. Granulocyte-Colony Stimulating Factor Reduces Cocaine-Seeking and Downregulates Glutamatergic Synaptic Proteins in Medial Prefrontal Cortex.
Hofford RS; Euston TJ; Wilson RS; Meckel KR; Peck EG; Godino A; Landry JA; Calipari ES; Lam TT; Kiraly DD
J Neurosci; 2021 Feb; 41(7):1553-1565. PubMed ID: 33361463
[TBL] [Abstract][Full Text] [Related]
60. Comorbid major depressive disorder as a prognostic factor in cocaine-abusing buprenorphine-maintained patients treated with desipramine and contingency management.
Gonzalez G; Feingold A; Oliveto A; Gonsai K; Kosten TR
Am J Drug Alcohol Abuse; 2003 Aug; 29(3):497-514. PubMed ID: 14510037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
